Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
16 févr. 2017 11h05 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 16, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017
08 févr. 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 8, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
02 févr. 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 2, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced...
Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference
23 janv. 2017 09h44 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 23, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in...
Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
05 janv. 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 5, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in controlling...
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
05 déc. 2016 18h03 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
31 oct. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 31, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
11 oct. 2016 08h10 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
15 sept. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
12 sept. 2016 19h07 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...